Recent Updates — CRSP

CRISPR Therapeutics AG promoted Andrew J. Silver from Senior Vice President of Finance to Chief Financial Officer, effective October 19, 2026. Mr. Silver will also serve as principal financial and accounting officer under a new employment agreement featuring a $515,000 annual base salary, a target bonus of 45 percent, and a one-time grant of 25,000 restricted stock units vesting in two years. Concurrently, outgoing CFO Raju Prasad resigned to pursue external opportunities but will remain employed through November 30, 2026. The company develops gene-editing therapies for serious diseases.

CRISPR Therapeutics AG reported financial results for the quarter ended June 30, 2026. The company generated $76 million in CASGEVY revenue, reflecting 151% year-over-year growth. Net loss narrowed to $91.2 million from $208.5 million in the prior year period, driven by reduced R&D and G&A expenses alongside increased collaboration revenue. Cash reserves rose to $2,364.4 million following a $585.4 million convertible senior notes issuance in March 2026. The FDA approved CASGEVY for children aged two and older with sickle cell disease or transfusion-dependent beta thalassemia. Additionally, the company initiated Phase 1 clinical trials for CTX340 targeting refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency. CRISPR Therapeutics AG is a biopharmaceutical company focused on developing transformative gene-based medicines using CRISPR/Cas9 technology.